Progress is most evident for stage I HER2-positive breast cancers, with the single-arm APT trial showing excellent long-term outcomes with adjuvant paclitaxel plus trastuzumab (TH), omitting doxorubicin and cyclophosphamide2,3. The gene discussed is ERBB2; the disease is breast carcinoma.